These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 27881285)

  • 1. Conventionally Fractionationed Volumetric Arc Therapy versus Hypofractionated Stereotactic Body Radiotherapy: Quality of Life, Side Effects, and Prostate-Specific Antigen Kinetics in Localized Prostate Cancer.
    Tambas M; Agaoglu F; Iribas A; Guveli M; Dizdar Y; Okutan M; Sahin D; Tenekeci N; Darendeliler E
    Value Health Reg Issues; 2016 Sep; 10():91-99. PubMed ID: 27881285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate-specific antigen kinetics following hypofractionated stereotactic body radiotherapy versus conventionally fractionated external beam radiotherapy for low- and intermediate-risk prostate cancer.
    Lee SH; Kim HJ; Kim WC
    Asia Pac J Clin Oncol; 2016 Dec; 12(4):388-395. PubMed ID: 27461444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First Australian experience of treating localised prostate cancer patients with CyberKnife stereotactic radiotherapy: early PSA response, acute toxicity and quality of life.
    Dixit A; Tang C; Bydder S; Kedda MA; Vosikova E; Bharat C; Gill S
    J Med Radiat Sci; 2017 Sep; 64(3):180-187. PubMed ID: 28271639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urinary Morbidity in Men Treated With Stereotactic Body Radiation Therapy (SBRT) for Localized Prostate Cancer Following Transurethral Resection of the Prostate (TURP).
    Pepin A; Aghdam N; Shah S; Kataria S; Tsou H; Datta S; Danner M; Ayoob M; Yung T; Lei S; Gurka M; Collins BT; Krishnan P; Suy S; Hankins R; Lynch JH; Collins SP
    Front Oncol; 2020; 10():555. PubMed ID: 32432033
    [No Abstract]   [Full Text] [Related]  

  • 5. SHARP hypofractionated stereotactic radiotherapy is well tolerated in prostate cancer : Toxicity and quality of life assessment.
    Rucinska M; Kieszkowska-Grudny A; Nawrocki S
    Strahlenther Onkol; 2016 Jul; 192(7):449-57. PubMed ID: 27221312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years.
    Katz AJ; Santoro M; Diblasio F; Ashley R
    Radiat Oncol; 2013 May; 8():118. PubMed ID: 23668632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Efficacy of Virtual Prostatectomy With Single-Dose Radiotherapy in Patients With Intermediate-Risk Prostate Cancer: Results From the PROSINT Phase 2 Randomized Clinical Trial.
    Greco C; Pares O; Pimentel N; Louro V; Santiago I; Vieira S; Stroom J; Mateus D; Soares A; Marques J; Freitas E; Coelho G; Seixas M; Lopez-Beltran A; Fuks Z
    JAMA Oncol; 2021 May; 7(5):700-708. PubMed ID: 33704378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate-specific antigen kinetics following hypofractionated stereotactic body radiotherapy boost and whole pelvic radiotherapy for intermediate- and high-risk prostate cancer.
    Kim HJ; Phak JH; Kim WC
    Asia Pac J Clin Oncol; 2017 Feb; 13(1):21-27. PubMed ID: 26969216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypofractionated SBRT versus conventionally fractionated EBRT for prostate cancer: comparison of PSA slope and nadir.
    Anwar M; Weinberg V; Chang AJ; Hsu IC; Roach M; Gottschalk A
    Radiat Oncol; 2014 Feb; 9():42. PubMed ID: 24484652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial.
    King CR; Brooks JD; Gill H; Pawlicki T; Cotrutz C; Presti JC
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1043-8. PubMed ID: 18755555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience.
    Chen LN; Suy S; Uhm S; Oermann EK; Ju AW; Chen V; Hanscom HN; Laing S; Kim JS; Lei S; Batipps GP; Kowalczyk K; Bandi G; Pahira J; McGeagh KG; Collins BT; Krishnan P; Dawson NA; Taylor KL; Dritschilo A; Lynch JH; Collins SP
    Radiat Oncol; 2013 Mar; 8():58. PubMed ID: 23497695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate specific antigen kinetics following robotic stereotactic body radiotherapy for localized prostate cancer.
    Kole TP; Chen LN; Obayomi-Davies O; Kim JS; Lei S; Suy S; Dritschilo A; Collins SP
    Acta Oncol; 2015 Jun; 54(6):832-8. PubMed ID: 25467965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stereotactic body radiotherapy as monotherapy or post-external beam radiotherapy boost for prostate cancer: technique, early toxicity, and PSA response.
    Jabbari S; Weinberg VK; Kaprealian T; Hsu IC; Ma L; Chuang C; Descovich M; Shiao S; Shinohara K; Roach M; Gottschalk AR
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):228-34. PubMed ID: 21183287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate-specific antigen kinetics following hypofractionated stereotactic body radiotherapy boost as post-external beam radiotherapy versus conventionally fractionated external beam radiotherapy for localized prostate cancer.
    Phak JH; Kim HJ; Kim WC
    Prostate Int; 2016 Mar; 4(1):25-9. PubMed ID: 27014661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stereotactic body radiation therapy for prostate cancer: a study comparing 3-year genitourinary toxicity between CyberKnife and volumetric-modulated arc therapy by propensity score analysis.
    Ito M; Yoshioka Y; Takase Y; Suzuki J; Takahashi H; Minami Y; Sakuragi A; Oshima Y; Okuda T; Suzuki K
    Radiat Oncol; 2023 Feb; 18(1):39. PubMed ID: 36823674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early and multiple PSA bounces can occur following high-dose prostate stereotactic body radiation therapy: Subset analysis of a phase 1/2 trial.
    Kim DN; Straka C; Cho LC; Lotan Y; Yan J; Kavanagh B; Raben D; Cooley S; Brindle J; Xie XJ; Pistenmaa D; Timmerman R
    Pract Radiat Oncol; 2017; 7(1):e43-e49. PubMed ID: 27637137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term results and PSA kinetics after robotic SBRT for prostate cancer: multicenter retrospective study in Korea (Korean radiation oncology group study 15-01).
    Park Y; Park HJ; Jang WI; Jeong BK; Kim HJ; Chang AR
    Radiat Oncol; 2018 Nov; 13(1):230. PubMed ID: 30470253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stereotactic body radiotherapy as boost for organ-confined prostate cancer.
    Katz AJ; Santoro M; Ashley R; Diblasio F; Witten M
    Technol Cancer Res Treat; 2010 Dec; 9(6):575-82. PubMed ID: 21070079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stereotactic body radiation therapy (SBRT) for prostate cancer in men with large prostates (≥50 cm(3)).
    Janowski E; Chen LN; Kim JS; Lei S; Suy S; Collins B; Lynch J; Dritschilo A; Collins S
    Radiat Oncol; 2014 Nov; 9():241. PubMed ID: 25398516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 2 Multicenter Trial of Heterogeneous-dosing Stereotactic Body Radiotherapy for Low- and Intermediate-risk Prostate Cancer: 5-year Outcomes.
    Fuller DB; Falchook AD; Crabtree T; Kane BL; Medbery CA; Underhill K; Gray JR; Peddada A; Chen RC
    Eur Urol Oncol; 2018 Dec; 1(6):540-547. PubMed ID: 31158102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.